Integrin subunit beta 8 contributes to lenvatinib resistance in HCC

Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wei, Bridgeman, Bryan, Malnassy, Greg, Ding, Xianzhong, Cotler, Scott J., Dhanarajan, Asha, Qiu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234648/
https://www.ncbi.nlm.nih.gov/pubmed/35238496
http://dx.doi.org/10.1002/hep4.1928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234648/
https://www.ncbi.nlm.nih.gov/pubmed/35238496
http://dx.doi.org/10.1002/hep4.1928

Ejemplares similares